Výsledky vyhledávání - "Cynthia Ten Eyck"

Data from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Autor: Paul Haluska, Scott H. Kaufmann, Charles Erlichman, Marco M. Gottardis, Douglas D. Ross, Jennifer D. Tibodeau, Takeo Nakanishi, Cynthia Ten Eyck, Yan W. Asmann, Karen Flatten, Joan M. Carboni, Fei Huang, Xiaonan Hou

Preclinical investigations have identified insulin-like growth factor (IGF) signaling as a key mechanism for cancer growth and resistance to clinically useful therapies in multiple tumor types including breast cancer. Thus, agents targeting and block

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0fbd5465fc9b4aaf920a287c41441376
https://doi.org/10.1158/1535-7163.c.6531158.v1

Zobrazit plný text záznamu

Supplementary Figure 1 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Supplementary Figure 1 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4d25a4bed8d23420c5d7d440792c19f
https://doi.org/10.1158/1535-7163.22483487.v1

Zobrazit plný text záznamu

Supplementary Figure 2B from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Supplementary Figure 2A from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10da2daab2cc7cd9211b62fde0a4a109
https://doi.org/10.1158/1535-7163.22483478

Zobrazit plný text záznamu

Supplementary Figure 3 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Supplementary Figure 3 from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f33a97bc95be6f189ea95696ab2ac63
https://doi.org/10.1158/1535-7163.22483475

Zobrazit plný text záznamu

Supplementary Figure Legends from Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c7d885e6742f7557bdf314277b02c6c
https://doi.org/10.1158/1535-7163.22483472.v1

Zobrazit plný text záznamu

Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

Autor: B. Douglas Smith, Nga T. Dai, Heather Powell, Benjamin T. Vroman, David A. Loegering, Judith E. Karp, Karen S. Flatten, Charles Erlichman, Scott H. Kaufmann, Ruben A. Mesa, Larry M. Karnitz, Sonnet J.H. Arlander, Cynthia Ten Eyck, Michael P. Heldebrant

Publikováno v: Blood. 106:318-327

Previous studies demonstrated that ataxia telangiectasia mutated– and Rad3-related (ATR) kinase and its downstream target checkpoint kinase 1 (Chk1) facilitate survival of cells treated with nucleoside analogs and other replication inhibitors. Rece

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66e1a763aa89ea4f7bb15dd86cb5f150
https://doi.org/10.1182/blood-2004-09-3523

Zobrazit plný text záznamu

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

Autor: Charles Erlichman, Bridget Stensgard, Gretchen N. Batzel, Joleen M. Hubbard, Sara J. Felten, Rui Qin, David O. Toft, Cynthia Ten Eyck, Paul Haluska, S. Percy Ivy

Publikováno v: Investigational new drugs. 29(3)

Purpose: To determine the maximum tolerated dose (MTD) and characterize the dose-limiting toxicities (DLT) of 17-AAG, gemcitabine and/or cisplatin. Levels of the proteins Hsp90, Hsp70 and ILK were measured in peripheral blood mononuclear cell (PMBC)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::028eefcacb6442beba3a28425b038c0a
https://pubmed.ncbi.nlm.nih.gov/20082116

Zobrazit plný text záznamu

Akademický článek

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.

Autor: Hubbard, Joleen, Erlichman, Charles, Toft, David, Qin, Rui, Stensgard, Bridget, Felten, Sara, Ten Eyck, Cynthia, Batzel, Gretchen, Ivy, S., Haluska, Paul

Publikováno v: Investigational New Drugs; Jun2011, Vol. 29 Issue 3, p473-480, 8p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání